- Home
- PCSA vs NEUP Comparison
PCSA vs NEUP Comparison
Compare PCSA & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCSA
- NEUP
- Stock Information
- Founded
- PCSA 2011
- NEUP 1996
- Country
- PCSA United States
- NEUP United States
- Employees
- PCSA N/A
- NEUP N/A
- Industry
- PCSA Biotechnology: Pharmaceutical Preparations
- NEUP
- Sector
- PCSA Health Care
- NEUP
- Exchange
- PCSA Nasdaq
- NEUP Nasdaq
- Market Cap
- PCSA 12.0M
- NEUP 12.7M
- IPO Year
- PCSA N/A
- NEUP N/A
- Fundamental
- Price
- PCSA $0.48
- NEUP $18.37
- Analyst Decision
- PCSA Strong Buy
- NEUP Strong Buy
- Analyst Count
- PCSA 1
- NEUP 2
- Target Price
- PCSA $1.00
- NEUP $28.00
- AVG Volume (30 Days)
- PCSA 21.2M
- NEUP 94.0K
- Earning Date
- PCSA 10-29-2025
- NEUP 11-15-2025
- Dividend Yield
- PCSA N/A
- NEUP N/A
- EPS Growth
- PCSA N/A
- NEUP N/A
- EPS
- PCSA N/A
- NEUP N/A
- Revenue
- PCSA N/A
- NEUP $15,649,448.00
- Revenue This Year
- PCSA N/A
- NEUP N/A
- Revenue Next Year
- PCSA N/A
- NEUP N/A
- P/E Ratio
- PCSA N/A
- NEUP N/A
- Revenue Growth
- PCSA N/A
- NEUP N/A
- 52 Week Low
- PCSA $0.15
- NEUP $2.90
- 52 Week High
- PCSA $1.50
- NEUP $126.00
- Technical
- Relative Strength Index (RSI)
- PCSA 86.63
- NEUP 69.20
- Support Level
- PCSA $0.19
- NEUP $10.47
- Resistance Level
- PCSA $0.21
- NEUP $21.31
- Average True Range (ATR)
- PCSA 0.04
- NEUP 1.84
- MACD
- PCSA 0.03
- NEUP 0.71
- Stochastic Oscillator
- PCSA 78.50
- NEUP 72.11
About PCSA Processa Pharmaceuticals Inc.
Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its regulatory science approach in the development of Next Generation Chemotherapy (NGC) oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small-molecule oncology drugs. The NGC products are new chemical entities, but the company works by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The three NGC treatments in its pipeline are PCS6422 (also referred to as NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem), and PCS11T, also referred to as NGC-Irinotecan (NGC-Iri).
About NEUP Neuphoria Therapeutics Inc. Common Stock
Neuphoria Therapeutics Inc is a clinical stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder.